Influenza is a disease of public health importance due to the substantial seasonal morbidity and mortality and the high pandemic potential of its aetiologic agents, influenza viruses.
This document presents the core protocol for ECDC studies of CVE and IVE against symptomatic laboratory-confirmed influenza or SARS-CoV-2 infection, respectively, at primary care level.
This study provides insights for national public health authorities into the factors behind the spread of vaccine misinformation online and the options and capacities needed for responding to it.
The influenza vaccination communication guide provide advice, guidance and campaign materials to support national influenza vaccination campaigns with the purpose of increasing the influenza vaccination uptake in the EU Member States.
The aim of this guidance document is to provide EU/EEA Member States and EU bodies with relevant information to make an informed decision on routine vaccination of healthy children and pregnant women with seasonal influenza vaccine. The options presented in this document are based on a systematic review of the literature and the opinions of a group of independent experts.
This publication presents the core European protocol for a series of proposed influenza vaccine effectiveness studies. The protocol includes a proposed plan for pooled analysis and has recently been adapted to measure vaccine effectiveness for the pandemic vaccine in 2009-10. Together with its twin publication ‘Protocols for cohort database studies to measure influenza vaccine effectiveness in the EU and EEA Member States’, this publication covers all methodological issues in the design and implementation of vaccine effectiveness studies, both for seasonal and the new A(H1N1)v influenza.
Antiviral drugs are an important addition to the public health arsenal against influenza. This interim guidance discusses the options for their effective use, especially during a pandemic.
This interim guidance outlines the possible strategies that countries may wish to adopt in the deployment of a pandemic-specific vaccine, considering the two objectives of vaccination: protecting those at greatest risk of severe disease and maintaining essential services.
This paper identifies and describes population groups at increased risk for severe outcomes of influenza (“risk groups”) and advocates vaccination for two major groups, namely a) persons in the older age group, usually 65 years and older; and b) persons with chronic medical conditions.